Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Masteron and RAD-140 Interaction: Monitor | Peptide Database

Compound Profiles Masteron DHT-Derived Anabolic Steroid | Hardening & Anti-Estrogenic Drostanolone binds to the androgen receptor with high affinity, promoting protein synthesis and nitrogen retention in skeletal muscle. As a DHT derivative, it cannot be conve

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Masteron

DHT-Derived Anabolic Steroid | Hardening & Anti-Estrogenic

Drostanolone binds to the androgen receptor with high affinity, promoting protein synthesis and nitrogen retention in skeletal muscle. As a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme, eliminating estrogen-related side effects such as water retention and gynecomastia from the compound itself.

RAD-140

Selective Androgen Receptor Modulator | Investigational SARM

RAD-140 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a full agonist in muscle and bone tissue while exhibiting minimal agonist activity in the prostate and other androgen-sensitive tissues. This tissue selectivity is achieved through differential cofactor recruitment: upon binding to the AR, RAD-140 induces a conformational change that favors interaction with coactivators predominantly expressed in skeletal muscle and bone, rather than those prevalent in prostate or sebaceous glands.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Masteron with RAD-140?

Yes, but with caution. Both Masteron and RAD-140 suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. Regular monitoring is advised.

Is Masteron and RAD-140 safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: androgenic, blood pressure raising, carcinogenic risk, hpta suppressive, lipid disrupting. Monitor accordingly.

What are the interactions between Masteron and RAD-140?

Both Masteron and RAD-140 suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. This assessment has 46% confidence and is inferred from pharmacological mechanism analysis.

How should I time Masteron and RAD-140?

Masteron has a half-life of ~2 days (propionate), ~10 days (enanthate) and RAD-140 has a half-life of ~60 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

Meta-analyses show modest cognitive improvements, though clinical significance remains debated. Multiple RCTs demonstrate significant ADAS-cog and CIBIC+ improvements. Large meta-analysis shows significant NIHSS improvements; other studies found no functional benefit. Largest meta-analysis (1,879 patients) shows NIHSS benefits; independent analysis found no mRS improvement. Multiple trials including CAPTAIN series confirm GCS/GOS improvements. Pilot trial shows promising 6-month outcomes; requires larger confirmatory studies. Some studies show enhanced recovery; results vary significantly between trials. Early administration within 72 hours shows better outcomes than delayed treatment.

Source: peptide-db.com ↗

Research Indications

Enhances memory consolidation and spatial learning in animal models through FGFR1-mediated synaptic plasticity. Preclinical evidence suggests potential to counteract age-related cognitive decline via neurogenesis and synaptic support. Animal studies demonstrate reduced infarct volume and improved functional outcomes following ischemic injury. Shows protective effects in preclinical models of Alzheimer's disease and other neurodegenerative conditions. Promotes long-term potentiation and strengthens synaptic connections through FGFR1 activation. Stimulates the generation of new neurons in the hippocampus in animal models.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Potential benefits

What are the cardiovascular benefits of B7-33 compared to other compounds?

B7-33 reduces myocardial fibrosis, enhances vasodilation through nitric oxide pathway, and demonstrates cardioprotective effects in heart failure models. These anti-fibrotic and vasoprotective properties position it for potential use in cardiac remodeling, though all current data is preclinical.

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides